Throughout the 1960’s and 1970's, the pharmaceutical industry focused almost exclusively on small molecule drugs to treat diseases. The 1980’s and 1990's witnessed the era of genetic engineering, resulting in the development of innovative biologics such as monoclonal antibodies and recombinant proteins, as well as the development of new tools to identify small molecule drugs. These transformational technologies helped start the biotechnology industry. As we enter the “Century of the Cell”, the advent of stem cell engineering offers the potential to produce true disease-modifying treatments and cures for many debilitating, degenerative disorders, including diabetes and cancer. Novo cell’s goal is to develop a renewable source of specialized cells that can be used to treat chronic cellular diseases. To achieve this goal, Novo cell is uniquely positioned to exploit human stem cell engineered product opportunities using its proprietary cell encapsulation technology. Combined with Novo cell’s expertise in cell transplantation, these technologies will allow large numbers of patients to be implanted with disease curing cells without the use of immunosuppression. Beginning with the treatment of diabetes, Novo cell’s technology platform has wide application to a range of diseases and conditions where the only effective treatment will be the replacement of non-functional cells. These include Parkinson’s disease, spinal cord injury, stroke, thyroid malfunction, and chronic liver failure.
Novo cell, Inc.
3550 General Atomics Court
Building 2-503
San Diego, CA 92121
Phone: (858) 455-3708
Fax: (858) 455-3962
Email: info@novocell.com
